Starpharma Holdings Limited

Symbol: SPHRF




Market price today

  • -3.0612

    P/E Ratio

  • -0.0314

    PEG Ratio

  • 40.83M

    MRK Cap

  • 0.00%

    DIV Yield

Starpharma Holdings Limited (SPHRF) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Ms. Cheryl Maley B.Sc., M.B.A.
Full-time employees:45
Address:4-6 Southampton Crescent

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

General Outlook

In simple terms, Starpharma Holdings Limited has 412.041 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.484% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -2.914%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -1.780%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.463% return, is a testament to Starpharma Holdings Limited's adeptness in optimizing resource deployment. Starpharma Holdings Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.513%. Furthermore, the proficiency of Starpharma Holdings Limited in capital utilization is underscored by a remarkable -0.904% return on capital employed.

Stock Prices

Starpharma Holdings Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.08, while its low point bottomed out at $0.08. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Starpharma Holdings Limited's stock market.

Liquidity Ratios

Analyzing SPHRF liquidity ratios reveals its financial health of the firm. The current ratio of 560.35% gauges short-term asset coverage for liabilities. The quick ratio (521.97%) assesses immediate liquidity, while the cash ratio (455.50%) indicates cash reserves.

Current Ratio560.35%
Quick Ratio521.97%
Cash Ratio455.50%

Profitability Ratios

SPHRF profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -271.71% underscores its earnings before tax deductions. The effective tax rate stands at 34.50%, revealing its tax efficiency. The net income per EBT, 65.50%, and the EBT per EBIT, 93.26%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -291.37%, we grasp its operational profitability.

Pretax Profit Margin-271.71%
Effective Tax Rate34.50%
Net Income per EBT65.50%
EBT per EBIT93.26%
EBIT per Revenue-291.37%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 5.60, it details the span from stock purchase to revenue. The 5 days it takes to settle debts showcases its creditor relations. Meanwhile, a 5 cash conversion cycle and 243.90% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding522
Days of Inventory Outstanding167
Operating Cycle317.06
Days of Payables Outstanding308
Cash Conversion Cycle9
Receivables Turnover2.44
Payables Turnover1.18
Inventory Turnover2.18
Fixed Asset Turnover2.60
Asset Turnover0.26

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.04, and free cash flow per share, -0.04, depict cash generation on a per-share basis. The cash per share value, 0.08, showcases liquidity position. Lastly, the operating cash flow sales ratio, -1.37, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.04
Free Cash Flow per Share-0.04
Cash per Share0.08
Operating Cash Flow Sales Ratio-1.37
Free Cash Flow to Operating Cash Flow Ratio1.05
Cash Flow Coverage Ratio-20.34
Short Term Coverage Ratio-20.34
Capital Expenditure Coverage Ratio-22.11
Dividend Paid and Capex Coverage Ratio-22.11

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.75%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.02, we discern the balance between debt and equity financing.

Debt Ratio1.75%
Debt Equity Ratio0.02
Total Debt to Capitalization2.19%
Cash Flow to Debt Ratio-20.34
Company Equity Multiplier1.28

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.01, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.04, reflects the portion of profit attributed to each share. The book value per share, 0.09, represents the net asset value distributed per share, while the tangible book value per share, 0.09, excludes intangible assets.

Revenue Per Share0.01
Net Income Per Share-0.04
Book Value Per Share0.09
Tangible Book Value Per Share0.09
Shareholders Equity Per Share0.09
Interest Debt Per Share0.02

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -37.23%, indicates top-line expansion, while the gross profit growth, -35.86%, reveals profitability trends. EBIT growth, -39.30%, and operating income growth, -39.30%, offer insights into operational profitability progression. The net income growth, 3.19%, showcases bottom-line expansion, and the EPS growth, 3.78%, measures the growth in earnings per share.

Revenue Growth-37.23%
Gross Profit Growth-35.86%
EBIT Growth-39.30%
Operating Income Growth-39.30%
Net Income Growth3.19%
EPS Growth3.78%
EPS Diluted Growth3.78%
Weighted Average Shares Growth0.52%
Weighted Average Shares Diluted Growth0.52%
Operating Cash Flow Growth-2.82%
Free Cash Flow Growth-1.11%
10-Year Revenue Growth per Share10077.18%
5-Year Revenue Growth per Share-30.23%
3-Year Revenue Growth per Share-55.67%
10-Year Operating CF Growth per Share4.31%
5-Year Operating CF Growth per Share-20.05%
3-Year Operating CF Growth per Share-14.29%
10-Year Net Income Growth per Share-107.12%
5-Year Net Income Growth per Share-37.59%
3-Year Net Income Growth per Share3.05%
10-Year Shareholders Equity Growth per Share-47.55%
5-Year Shareholders Equity Growth per Share-40.87%
3-Year Shareholders Equity Growth per Share1.14%
Receivables Growth5.09%
Inventory Growth-1.81%
Asset Growth-21.29%
Book Value per Share Growth-28.43%
Debt Growth1.01%
R&D Expense Growth61.56%
SGA Expenses Growth113.41%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 105,138,302.91, captures the company's total value, considering both debt and equity. Income quality, 0.87, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 1.28, gauges operational efficiency, while the research and development to revenue, 642.06%, highlights investment in innovation.

Enterprise Value105,138,302.91
Income Quality0.87
Sales General and Administrative to Revenue1.28
Research and Development to Revenue642.06%
Capex to Operating Cash Flow4.59%
Capex to Revenue-21.13%
Capex to Depreciation-52.05%
Stock-Based Compensation to Revenue70.09%
Graham Number0.27
Return on Tangible Assets-30.02%
Graham Net Net0.06
Working Capital32,649,000
Tangible Asset Value34,815,000
Net Current Asset Value29,851,000
Average Receivables8,035,499.5
Average Payables6,688,500
Average Inventory2,798,500
Days Sales Outstanding1023
Days Payables Outstanding1407
Days of Inventory On Hand590

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.81, and the price to book ratio, 1.81, reflect the market's valuation relative to the company's book value. The price to sales ratio, 5.46, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -3.82, and price to operating cash flows, -3.98, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.81
Price to Book Ratio1.81
Price to Sales Ratio5.46
Price Cash Flow Ratio-3.98
Price Earnings to Growth Ratio-0.03
Enterprise Value Multiple-2.91
Price Fair Value1.81
Price to Operating Cash Flow Ratio-3.98
Price to Free Cash Flows Ratio-3.82
Price to Tangible Book Ratio3.79
Enterprise Value to Sales35.77
Enterprise Value Over EBITDA-4.48
EV to Operating Cash Flow-7.77
Earnings Yield-11.84%
Free Cash Flow Yield-10.72%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Starpharma Holdings Limited (SPHRF) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.061 in 2024.

What is the ticker symbol of Starpharma Holdings Limited stock?

The ticker symbol of Starpharma Holdings Limited stock is SPHRF.

What is company IPO date?

IPO date of Starpharma Holdings Limited is 2007-04-30.

What is company current share price?

Current share price is 0.099 USD.

What is stock market cap today?

The market cap of stock today is 40833263.000.

What is PEG ratio in 2024?

The current -0.031 is -0.031 in 2024.

What is the number of employees in 2024?

In 2024 the company has 45.